The spectrum of multiple sclerosis (MS) in Latin America is characterized by geographic and racial/genetic particularities. In this review we describe major studies of MS epidemiology, genetics, and clinical presentation in Latin America, with a focus on Colombia. We also consider the influence of national health care systems on the treatment of MS in Latin American patients. Epidemiologic studies indicate that the regional incidence of MS in Latin America is more complex than once thought, and broadly consistent with the geographical (latitudinal) distribution of MS in other parts of the world. Low prevalence of MS is considered to be <5/100.000 inhabitants and high prevalence >30/100,000. Colombia is considered a low-risk region for MS, as are other countries located near the equator, such as Panama and Ecuador. By contrast, Latin American countries located farther from the equator are medium or high-risk regions. National health care systems generally cover MS treatment, although bureaucratic problems sometimes interfere with delivery of high-cost medications and access to diagnostic tests, particularly in rural areas. The population of Colombia is racially diverse and genetically heterogeneous, making it difficult to study genetic associations within a complex disease such as MS. The clinical spectrum of MS in Latin America is similar to that of Europe or North America.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2012.09.001 | DOI Listing |
CJC Open
January 2025
Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Background: Primary percutaneous coronary intervention (PCI) is the established treatment for ST-segment elevation myocardial infarction (STEMI), but often it is not readily available in low-resource settings. We assessed the safety and efficacy of the pharmaco-invasive strategy compared to primary PCI for STEMI in Latin America.
Methods: MEDLINE, Embase, and Latin American and Caribbean Health Sciences Literature (LILACS) were searched for the period from their inception to September 2023, for studies that compared a pharmaco-invasive strategy vs primary PCI in Latin America.
Heliyon
January 2025
Directorate of Research, Development and Technological Innovation, Ophthalmological Foundation of Santander (FOSCAL), Floridablanca, Colombia.
Introduction: Cardiovascular diseases are the leading cause of death and morbidity worldwide, with a significantly higher burden in low- and middle-income countries. Hypertension, a major risk factor for cardiovascular morbidity and mortality, remains under-diagnosed and poorly controlled, especially in regions such as Latin America. The HOPE-4 study demonstrated that the involvement of non-physician health workers (NPHWs), the use of standardized treatment algorithms, the provision of free antihypertensive drugs and home follow-up can significantly improve hypertension control and reduce cardiovascular risk, as demonstrated in Colombia and Malaysia.
View Article and Find Full Text PDFClin Transl Immunology
January 2025
Infectious Diseases Group, Infection, Immunity and Global Health Theme Murdoch Children's Research Institute Parkville VIC Australia.
Objectives: Bacille Calmette-Guérin (BCG) vaccination has off-target effects on disease risk for unrelated infections and immune responses to vaccines. This study aimed to determine the immunomodulatory effects of BCG vaccination on immune responses to vaccines against SARS-CoV-2.
Methods: Blood samples, from a subset of 275 SARS-CoV-2-naïve healthcare workers randomised to BCG vaccination (BCG group) or no BCG vaccination (Control group) in the BRACE trial, were collected before and 28 days after the primary course (two doses) of ChAdOx1-S (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccination.
Front Nutr
January 2025
Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China.
Background: The 2021 Global Burden of Disease (GBD) study shows a continuous increase in the burden of chronic kidney disease due to diabetes mellitus type 2 (CKD-T2DM) from 1990 to 2021. This study examines the influence of dietary risk factors across various populations and socioeconomic groups.
Methods: Utilizing the 2021 GBD data, we analyzed age-standardized CKD-T2DM metrics-including mortality, disability-adjusted life years (DALY), and age-standardized rates (ASR)-stratified by age, gender, and region.
SAGE Open Med
January 2025
Endocrinology Diabetes, Metabolism, and Obesity Medicine, Obesity, Endocrine, and Metabolism Center (OEMC), King Fahad Medical City (KFMC), Riyadh, Saudi Arabia.
Objectives: To explore the impact of obesity on clinical outcomes, health-related quality of life, emotional well-being, and work productivity in people/patients with obesity across six countries by body mass index and the presence of complications.
Methods: Adelphi Real World Obesity Disease Specific Programme™ captured data related to physicians and their consulting people/patients with obesity on a weight management program or anti-obesity medication in Brazil, Canada, China, Japan, Kingdom of Saudi Arabia, and the United Arab Emirates from April to December 2022. Physicians reported data for up to eight qualifying people/patients with obesity.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!